Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. J Surg Oncol 2010; 101:687-92; PMID:20512944; http://dx.doi.org/10.1002/jso.21455
   PubMed Web of Science ®Google Scholar
• Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006; 6:307-20; PMID:16557282; http://dx.doi.org/10.1038/nrc1837
   PubMed Web of Science ®Google Scholar
• Soulsby M, Bennett AM. Physiological signaling specificity by protein tyrosine phosphatases. Physiology (Bethesda) 2009; 24:281-9; PMID:19815854; http://dx.doi.org/10.1152/physiol.00017.2009
   PubMed Web of Science ®Google Scholar
• Lessard L, Stuible M, Tremblay ML. The two faces of PTP1B in cancer. Biochim Biophys Acta. 2010; 1804:613-9; PMID:19782770; http://dx.doi.org/10.1016/j.bbapap.2009.09.018
   PubMed Web of Science ®Google Scholar
• Brown-Shimer S, Johnson KA, Hill DE, Bruskin AM. Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Cancer Res 1992; 52:478-82; PMID:1345814
   PubMed Web of Science ®Google Scholar
• Sangwan V, Paliouras GN, Cheng A, Dube N, Tremblay ML, Park M. Protein-tyrosine phosphatase 1B deficiency protects against fas-induced hepatic failure. J Biol Chem 2006; 281:221-8; PMID:16234234; http://dx.doi.org/10.1074/jbc.M507858200
   PubMed Web of Science ®Google Scholar
• Zheng LY, Zhou DX, Lu J, Zhang WJ, Zou DJ. Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma. Biochem Biophys Res Commun 2012; 420:680-4; PMID:22450318; http://dx.doi.org/10.1016/j.bbrc.2012.03.066
   PubMed Web of Science ®Google Scholar
• Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC Jr. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 1994; 86:372-8; PMID:7905928; http://dx.doi.org/10.1093/jnci/86.5.372
   PubMed Web of Science ®Google Scholar
• Zhu S, Bjorge JD, Fujita DJ. PTP1B contributes to the oncogenic properties of colon cancer cells through src activation. Cancer Res 2007; 67:10129-37; PMID:17974954; http://dx.doi.org/10.1158/0008-5472.CAN-06-4338
   PubMed Web of Science ®Google Scholar
• Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, Tremblay ML. PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Res 2012; 72:1529-37; PMID:22282656; http://dx.doi.org/10.1158/0008-5472.CAN-11-2602
   PubMed Web of Science ®Google Scholar
• Wang J, Liu B, Chen X, Su L, Wu P, Wu J, Zhu Z. PTP1B expression contributes to gastric cancer progression. Med Oncol 2012; 29:948-56; PMID:21442314; http://dx.doi.org/10.1007/s12032-011-9911-2
   PubMed Web of Science ®Google Scholar
• Schwab M. Amplification of oncogenes in human cancer cells. Bioessays 1998; 20:473-9; PMID:9699459; http://dx.doi.org/10.1002/(SICI)1521-1878(199806)20:6%3c473::AID-BIES5%3e3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012; 12:50; PMID:22292935; http://dx.doi.org/10.1186/1471-2407-12-50
   PubMed Web of Science ®Google Scholar
• Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P, Ji M. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 2012; 13:4714-26; PMID:22606006; http://dx.doi.org/10.3390/ijms13044714
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang Z, Luo Y, Xu Y, Liu Y, Yang W, Zhang X. Analysis of DNA copy number aberrants by multiple ligation-dependent probe amplification on 50 intestinal typegastric cancers. J Surg Oncol 2011; 103:124-32; PMID:21259245; http://dx.doi.org/10.1002/jso.21792
   PubMed Web of Science ®Google Scholar
• Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8:86-94; PMID:15864715; http://dx.doi.org/10.1007/s10120-005-0320-0
   PubMedGoogle Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74; PMID:11990853; http://dx.doi.org/10.1038/nrc745
   PubMed Web of Science ®Google Scholar
• Peng Z, Wang CX, Fang EH, Wang GB, Tong Q. Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J Gastroenterol 2014; 20:5403-10; PMID:24833870; http://dx.doi.org/10.3748/wjg.v20.i18.5403
   PubMed Web of Science ®Google Scholar
• Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424:53-65; PMID:23669186; http://dx.doi.org/10.1016/j.cca.2013.05.002
   PubMed Web of Science ®Google Scholar
• Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009; 15:752-7; PMID:19188143; http://dx.doi.org/10.1158/1078-0432.CCR-08-0124
   PubMed Web of Science ®Google Scholar
• Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24:7410-25; PMID:16288288; http://dx.doi.org/10.1038/sj.onc.1209086
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang N, Hadden TJ, Rishi AK. 2011 Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813:1978-86; PMID:21440011; http://dx.doi.org/10.1016/j.bbamcr.2011.03.010
   PubMed Web of Science ®Google Scholar
• Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10:138-48; PMID:18204439; http://dx.doi.org/10.1038/ncb1676
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 2001; 10:383-92; PMID:11382593
   PubMedGoogle Scholar
• Sutter AP, Zeitz M, Scherübl H. Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 2004; 27:17-21; PMID:15007244; http://dx.doi.org/10.1159/000075600
   PubMed Web of Science ®Google Scholar
• Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10:643-55; PMID:24061039; http://dx.doi.org/10.1038/nrclinonc.2013.170
   PubMed Web of Science ®Google Scholar
• Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D. Forkhead box-O transcription factor: critical conductors of cancer's fate. Endocr Relat Cancer 2008; 15:917-29; PMID:18775975; http://dx.doi.org/10.1677/ERC-08-0153
   PubMed Web of Science ®Google Scholar
• Yang XB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X, et al. Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastricadenocarcinoma patients. PLoS One 2013; 8:e78158; PMID:24194912; http://dx.doi.org/10.1371/journal.pone.0078158
   PubMedGoogle Scholar
• Yang JY, Hung MC. Deciphering the role of forkhead transcription factors in cancer therapy. Curr Drug Targets 2011; 12:1284-90; PMID:21443462; http://dx.doi.org/10.2174/138945011796150299
   PubMed Web of Science ®Google Scholar
• Egan C, Pang A, Durda D, Cheng HC, Wang JH, Fujita DJ. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 1999; 18:1227-37; PMID:10022129; http://dx.doi.org/10.1038/sj.onc.1202233
   PubMed Web of Science ®Google Scholar
• Martin GS. The road to Src. Oncogene 2004; 23:7910-7; PMID:15489909; http://dx.doi.org/10.1038/sj.onc.1208077
   PubMed Web of Science ®Google Scholar
• Chen T, George JA, Taylor CC. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anticancer Drugs 2006; 17:123-31; PMID:16428929; http://dx.doi.org/10.1097/00001813-200602000-00002
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang ZY. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 2007; 12:373-81; PMID:17467573; http://dx.doi.org/10.1016/j.drudis.2007.03.011
   PubMed Web of Science ®Google Scholar
• Lee S, Wang Q. Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. Med Res Rev 2007; 27:553-73; PMID:17039461; http://dx.doi.org/10.1002/med.20079
   PubMed Web of Science ®Google Scholar
• Krishnan N, Koveal D, Miller DH, Xue B, Akshinthala SD, Kragelj J, Jensen MR, Gauss CM, Page R, Blackledge M, et al. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat Chem Biol 2014; 10:558-66; PMID:24845231; http://dx.doi.org/10.1038/nchembio.1528
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:103-43; PMID:17463250
   PubMed Web of Science ®Google Scholar
• Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007; 13:1161-70; PMID:17317825; http://dx.doi.org/10.1158/1078-0432.CCR-06-1125
   PubMed Web of Science ®Google Scholar
• Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011; 11:147; PMID:21507233; http://dx.doi.org/10.1186/1471-2407-11-147
   PubMed Web of Science ®Google Scholar